期刊文献+

氯沙坦对原发性高血压患者尿蛋白排泄的影响

Effect of Losartan on the Excretion of Urine Protein in Essential Hypertension
下载PDF
导出
摘要 目的 :探讨氯沙坦对原发性高血压肾功能损害的影响。方法 :选择 54例EH患者和NC组 30例 ,氯沙坦 50mg ,每天 1次 ,治疗 4周 ,比较EH与NC组及EH组用药前后肾功能和尿蛋白的改变。结果 :EH组 2 4hUTP、2 4hUAlb明显高于NC组 ,EH组氯沙坦治疗 4周后2 4hUTP、2 4hUAlb、2 4hα1 MG、2 4hβ2 MG排泄率明显低于治疗前。结论 :氯沙坦对EH患者有良好的早期保护肾功能作用。 Objective:To discuss the effect of losartan on impairment of renal function in essential hypertension(EH). Methods: 54 EH patients and 30 normal controls were studied. After 4 weeks treatments by losartan 50mg per day, the changes of renal function and urine protein were compared between EH group and NC group,and the pre and post treatment changes in EH group. Results: Before treatment, 24h UTP, 24h UAlb in EH is obviously higher than those in NC(P<0.05). In EH group, the excretion of 24h UTP,24h UAlb,24h Uα 1MG,24h Uβ 2MG decreased significantly after 4 weeks treatment with losartan(P<0.05). Conclusion:Losartan has satisfactory effect on earlier protection of renal function in EH patients.
出处 《沈阳医学院学报》 2002年第3期146-148,共3页 Journal of Shenyang Medical College
关键词 氯沙坦 原发性高血压 尿蛋白排泄 尿蛋白 Α1微球蛋白 Β2微球蛋白 essential hypertension losartan urine protein α 1microglobulin β 2microglobulin
  • 相关文献

参考文献5

  • 1Floege J, Alpers CE, Burn MW, et al. Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kindney model[J]. Lab Invest,1992,66:485.
  • 2Dunn FW,Roux MH, Farhadian F,et al. HR720, a novel angiotensin receptor antagonist inhibits the angiotensin Ⅱ-induced trophic effects, fibronectin release and fibronectin-E Ⅲ A experssion in rat aortic and vascular smooth muscle cells in vitro[J]. J Pharmacol Exp Ther, 1977,280:447.
  • 3Vaughan DE, Laszos SA, Tong K. Angiotensin Ⅱ regulate expression of plasminongen activator inhibitor 1 in cultured endothelial cells[J]. J Clin Invast, 1995,995.
  • 4Holdaas H, Hartmann A, Berg K J, et al. Renal effects of Iosartan and amlodipine in hypertensive patients with non-diabetic nephropathy[J]. Nephrol Dial Tranplant, 1998,13 (12) :3096.
  • 5张湘兰.血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体拮抗剂的特点及临床应用[J].辽宁药物与临床,2002,5(1):1-3. 被引量:2

二级参考文献15

  • 1[1]Cushman DW,Wang WL,Hancy CM,et al.Differentiation of angiotensin converting enzyme inhibitors by their selective inhibition of ACE in physiologically important target organs[J].Am J Hypertens,1989,2:294-306.
  • 2[2]Grover GJ,Sleph PG,Dzwonezyk S,Effects of different angiotensin converting enzyme(ACE) inhibitors on ischemic isolated rat hearts;relationship between cardiac ACE inhibition and cardioprotection[J].J Pharmacol Exp Ther,1991,257:919-929.
  • 3[3]Lorrel BH.Diastolic dysfunction in pressure-overload hypertrophy and its modification by angiotensin H:currentconcepts[J].Basic Res Cardiol,1992,87(suppl2):163-426.
  • 4[4]Vinci JM,Horowitz D,Zusman RM,et al.The effect of converting enzyme inhibition with SQ 10881 on plasma and urinary kinins,prostaglandin E and angiotensin Ⅱ in hypertensive man[J].Hypertension,1979,1:416-426.
  • 5[5]Kaplan NM.Systemic hypertension:therapy in Braunwald E.ED.Heart Disease[J].Philadelphia:WB Saunders,1992,852-874.
  • 6[6]Cutler JA,MacMahan S,Furburg CD.Controlled clinical trials of drug treatment for hypertension[J].A review,Hypertension,1989:13(suppl 1):136-144.
  • 7[7]Schoenberger JA.Antihypertensive drug therapy and coronary heart disease risk[J].J Fam Pract,1993,36:70-84.
  • 8[8]Inman WHW,Rawson NSB,Wilton LV,et al.Postmarketing surveillance of enalapril I:Results of prescription-event monitoring[J].BMJ,1988,826-829.
  • 9[9]Huckell VF,Belanger LG,Kazimirski M,et al.Lisinopril in the treatment of hypertension:A Canadian Postmarketing surveillance study[J].Clin Ther,1993,15:407-422.
  • 10[10]Dzau V,Julius S,Weber MA,for the ADOPT Study Group.ADOPT trial results:Comparison of response rates by age,race,medical history[J].AM J Hypertens,1994,7:123 A.Abstract J13.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部